Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066804 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,572
- Enrollment target
NCT03066804 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,572 participants.
The verdict
NCT03066804, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,572 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction (HFpEF).
Interventions
- DRUG Valsartan
- DRUG sacubitril/valsartan
- DRUG Enalapril
- DRUG Placebo to match sacubitril/valsartan
- DRUG Placebo to match enalapril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,572 participants |
| Start Date | 2017-08-22 |
| Est. Completion | 2019-10-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03066804
The ClinicalTrials.gov registry entry for NCT03066804 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,572 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Valsartan is the first listed.
NCT03066804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03066804 about?
NCT03066804 is a clinical study titled "A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients". The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction...
What is the current status of trial NCT03066804?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,572 participants. The study started on 2017-08-22. Estimated completion is 2019-10-28.
What interventions are being tested in trial NCT03066804?
The interventions under investigation include: Valsartan (DRUG), sacubitril/valsartan (DRUG), Enalapril (DRUG), Placebo to match sacubitril/valsartan (DRUG), Placebo to match enalapril (DRUG).
Who is sponsoring clinical trial NCT03066804?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.